^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600E + PD-L1 expression

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126; 673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    PD-L1 Expression in Anaplastic Thyroid Carcinoma: A Transcontinental Study of 151 Cases (USCAP 2023)
    In this large-scale study evaluating PD-L1 expression in ATC specimens, most of the ATCs were PD-L1-positive, which provides a rationale for immunotherapy in this aggressive malignancy. The positivity rate was lower in small biopsy specimens, having implications for clinical decision-making and formulation of management guidelines. PD-L1 expression did not correlate with BRAF V600E or TERT promoter mutation status.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    PD-L1 expression • BRAF V600E • BRAF V600 • PD-L1 negative • TERT mutation • BRAF V600E + TERT mutation • TERT promoter mutation • BRAF V600E + PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay